Abstract
INTRODUCTION
Functional gastrointestinal (GI) disorders are symptombased conditions that are not explained by definable structural or biochemical causes [1] . The prevalence of at least one functional GI disorder in the last 3 mo has been reported to be as high as 69% in the general population [2] . Slow intestinal transit is a common symptom of functional GI disorders, particularly those involving the bowel [3] . Therapies intended to ameliorate GI-related symptoms by decreasing intestinal transit time (ITT), such as laxatives, are a mainstay treatment of slow-transit bowel disorders although no known therapy is highly efficacious, safe, and cost effective [4] . Probiotics are live micro-organisms that confer a health benefit on the host when administered in adequate dosages [5] , which have been extensively studied for treatment of functional GI disorders [6, 7] . Additionally, there is speculation that probiotics may even improve gut health in healthy adults. For example, the European Food Safety Authority (EFSA) guidance on health claims related to gut function states that reduced ITT may be considered a beneficial physiological effect in the nondiseased general population, provided that diarrhea does not develop [8] . Consequently, ITT often serves as a primary study endpoint in probiotic clinical trials of gut health.
Based on the recent emphasis in this study endpoint in clinical trials and because accurate estimates of ITT effect size are mandatory for performing power calculations and estimating sample size in clinical trials, we performed the first systematic review and meta-analysis on the efficacy of probiotic supplementation on ITT in adults.
MATERIALS AND METHODS
The main objective of this systematic review and metaanalysis of RCTs was to assess the efficacy of probiotic supplementation on ITT in adults. The PRISMA Statement for reporting systematic reviews and meta-analyses served as a template for this report [9] .
Eligibility criteria and information sources
Studies that were eligible for consideration in this systematic review were RCTs published in English-language journals and indexed in MEDLINE or EMBASE with no date restrictions on the effects of probiotic supplementation on ITT in adults. The following search terms were used for probiotic supplementation (with "*" characterizing a wildcard and "OR" being used as a Boolean function): probiotic*; lactobacill*; bifidobacteri*; yogurt; yoghurt; fermented milk. The following search terms were used for ITT: gastrointestinal; transit; gut; motility; colonic; constipation; irritable bowel. To identify clinical trials, we applied the filters Clinical Trial or Randomized Controlled Trial. The results of each of the three sections were combined by utilizing the "AND" Boolean. In addition, we attempted to identify additional studies by hand-searching references of included studies and relevant review articles.
Study selection
One reviewer (Miller LE) initially assessed study eligibility. Titles and abstracts were screened to exclude all manuscripts published in non-English journals. Next, review articles, commentaries, letters, and case reports were excluded. We also excluded obviously irrelevant articles. Lastly, we excluded studies of subjects where ITT reduction was undesirable or uninterpretable (i.e., subjects with diarrhea or cohorts with multiple IBS subtypes). Full-text of the remaining manuscripts was retrieved and reviewed. Publications that failed to report ITT or that described non-randomized, non-controlled, or otherwise irrelevant studies were excluded. The last search was performed in December 2012.
Data collection process
Data were extracted and entered into a pre-designed database by one reviewer (Miller LE) and the entries were checked by the other reviewer (Ouwehand AC). Disagreements were settled by consensus.
Data items
The following variables were recorded in a pre-designed database: general manuscript information (author, in-
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August 7, 2013|Volume 19|Issue 29| WJG|www.wjgnet.com stitution name and location, journal, year, volume, page numbers), study design characteristics (study quality, study design, sample size, method of ITT assessment, probiotic strain, daily dosage, product delivery method, and treatment duration), subject characteristics (age, gender, body mass index, and condition), and ITT before and after probiotic supplementation.
Quality assessment
We used the Jadad scale to assess study quality of RCTs [10] . Studies were scored according to the presence of three key methodological features: randomization, blinding and subject accountability. Randomization was scored from 0 to 2 with 2 implying appropriate methods of randomization were described, 1 if the study was merely described as "randomized", and 0 when no details were provided to evaluate randomization. A score of 0 was given if the study was described as randomized, but the method of randomization was clearly inappropriate. Similarly, blinding was scored from 0 to 2 with 2 points awarded if subjects and investigators were blinded using appropriate methods, 1 point if the study was described merely as blinded, and 0 points if the study was described as blinded, but the method of blinding was clearly inappropriate. Subject accountability was scored 0 or 1 with 1 point awarded if all subjects were accounted for in the analysis and reasons for withdrawals were provided. A score of 0 was given when information regarding withdrawals was incomplete. A priori, studies with a Jadad score of 3 to 5 were deemed higher quality and those with a score of 0 to 2 were classified as lower quality.
Statistical analysis
A random effects meta-analysis model was selected a priori based on the assumption that the true effect may vary among studies based on known differences in probiotic strain, study design characteristics, and subject characteristics. The standardized mean difference (SMD) and 95%CI was selected to report treatment effects because different measures of ITT (e.g., whole gut, colonic, oro-cecal, etc.) were utilized in the included studies. The SMD is a measure of effect size for continuous outcomes defined as the mean difference between groups divided by the pooled standard deviation. SMD values of 0.2, 0.5 and 0.8 are defined as small, medium, and large, respectively [11] . A forest plot was used to illustrate the individual study findings and the random effects meta-analysis results. We used the I 2 statistic to estimate heterogeneity of effects across studies with values of ≤ 25%, 50%, and ≥ 75% representing low, moderate, and high inconsistency, respectively [12] . An alpha error P < 0.05 and/or I 2 ≥ 50% were taken as indicators of substantial heterogeneity of treatment effects. Publication bias was visually assessed with a funnel plot (not shown) and quantitatively assessed using Egger's test [13] . Metaregressions and pre-defined subgroup analyses were undertaken to quantify the relationship of individual moderators on ITT SMD. All analyses were performed using Comprehensive Meta-analysis (version 2.2, Biostat, Englewood, NJ, United States).
RESULTS

Study selection
Our initial database search retrieved 409 titles and abstracts and hand searching relevant bibliographies identified 3 additional records. After screening records for inclusion criteria, 73 full text articles were reviewed for eligibility. Ultimately, 11 RCTs with 13 treatment effects representing 464 distinct subjects were included in the final analysis [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . A flow chart of study identification and selection is shown in Figure 1 .
Study characteristics
Sample sizes were generally small, ranging from 10 to 36 per treatment group for parallel groups designs and from 12 to 83 for cross-over designs. The average detectable effect size, based on sample size and study design by assuming P = 0.05 and statistical power = 80%, was 0.8 (range: 0.3 to 1.3). Eleven RCTs contributed one treatment effect each. The study of Rosenfeldt et al [21] contributed two treatment effects (two different probiotic formulations) and the study of Waller et al [23] contributed two treatment effects (same probiotic strain, two different dosages). Eight of the 11 studies were parallel groups designs while 3 were cross-over studies. The most commonly studied probiotic strains were Bifidobacterium lactis (B. lactis) DN-173 010 (3 treatment effects), B. lactis HN019 (2 treatment effects), and Lactobacillus rhamnosus (L. rhamnosus) GG (2 treatment effects). Daily probiotic dosages varied substantially across studies, ranging from 5 × 10 8 to 9.75 × 10 10 cfu per day (median 1.72 × 10 10 cfu per day). Supplementation periods ranged from 10 to 28 d (median 18 d). Intestinal transit time was quantified using radiopaque markers in 10 studies and with carmine red dye in 1 study [19] . The most commonly [19] Crossover
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OCTT [20] Crossover Rosenfeldt et al [21] Crossover Rosenfeldt et al [21] Crossover tested product format was yogurt or other forms of fermented milk. Two studies were confounded by inclusion of other components in the active product that may influence ITT such as lactulose [15] and the combination of inulin and oligofructose [19] (Table 1) . Seven treatment effects were calculated based on subjects with constipation or irritable bowel syndrome-C while 6 were based on healthy subjects. Subjects were predominantly female with a mean age ranging from 23 to 50 years and mean body mass index ranging from 21 to 32 kg/m 2 (Table 2 ).
Study quality assessment
Overall, the quality of RCT reporting was medium with a median Jadad score of 3 (range: 1-5). Eight of 13 treatment effects were based on higher quality (Jadad score 3-5) trials. The method of randomization was unclear in most studies. Descriptions of blinding were adequate overall. Subject accountability in RCTs was mentioned in only 7 of 13 cases (Table 3) .
Synthesis of results
Overall, probiotic supplementation was associated with reduced ITT, with an SMD of 0.40 (95%CI: 0.20-0.59, P < 0.001) (Figure 2 ). There was low heterogeneity among studies (I 2 = 29%, P = 0.15) with no evidence of publication bias (Egger's regression test: P = 0.13). Only 4 of 13 individual treatment effects statistically favored probiotic supplementation.
Additional analyses
We performed meta-regression analysis including predefined covariates to explore the potential predictors of SMD. Constipation (r 2 = 39%, P = 0.01), higher mean age (r 2 = 27%, P = 0.03), and higher percentage of female subjects (r 2 = 23%, P < 0.05) were predictive of decreased ITT with probiotics in meta-regression (Table  4) . Additionally, we performed a pre-defined subgroup analysis to observe the influence of study-and subjectrelated characteristics on SMD (Table 5 ). Subgroup analyses demonstrated statistically greater reductions in ITT with probiotics in subjects with vs without constipation and in older vs younger subjects (both SMD: 0.59 vs 0.17, P = 0.01). Study design, body mass index, treatment duration, and daily probiotic dosage had no influence on probiotic treatment effects in any analysis. Analysis of outcomes by probiotic strain identified medium to large treatment effects with B. lactis HN019 (SMD: 0.72, P < 0.01) and B. lactis DN-173 010 (SMD: 0.54, P < 0.01) while treatment effects with other single strains and combination products were small (SMD: 0.17-0.25) and not statistically significant (Table 6 ).
DISCUSSION
Summary of evidence
Clinical trials of probiotic supplementation often utilize ITT as a primary efficacy outcome. However, inconsistent treatment effects among trials have been observed, likely due to differences among study designs, probiotic strains, dosing regimens, and subject characteristics. We performed the first systematic review and meta-analysis on this 
Condition
Agrawal et al [14] 40 100% 25 IBS-C Bartram et al [15] 23 58% -None Bouvier et al [16] 33 50% 22 None Holma et al [17] 44 92% 1 24 Constipation Hongisto et al [18] 43 100% 24 Constipation Malpeli et al [19] 41 100% -Constipation Marteau et al [20] 27 100% 21 None Rosenfeldt et al [21] 25 0% -None Rosenfeldt et al [21] 25 0% -None Sairanen et al [22] 39 64% 25 None Waller et al [23] 44 65% 31 Constipation Waller et al [23] 44 65% 32 Constipation Krammer et al [24] 50 100% -Constipation 1 Percentage estimated from larger study cohort. BMI: Body mass index; IBS-C: Irritable bowel syndrome, constipation predominant; "-": Represents missing data. Agrawal et al [14] 1 2 1 4 Bartram et al [15] 1 2 0 3 Bouvier et al [16] 1 2 0 3 Holma et al [17] 1 0 1 2 Hongisto et al [18] 1 0 0 1 Malpeli et al [19] 0 2 1 3 Marteau et al [20] 1 2 1 4 Rosenfeldt et al [21] 1 1 0 2 Rosenfeldt et al [21] 1 1 0 2 Sairanen et al [22] 1 1 0 2
Waller et al [23] 2 2 1 5 Waller et al [23] 2 2 1 5 Krammer et al [24] 1 1 1 3 We also demonstrated that the treatment effect of probiotics is strongly dependent on: (1) the presence or absence of constipation; (2) subject age; and (3) probiotic strain.
Clinical relevance of findings
Presence of constipation and older age were predictive of greater ITT treatment effects with probiotic supplementation. Constipation was the primary influencer of probiotic treatment effects on ITT, explaining 39% of the variance in SMD. The independent influence of subject age, after accounting for constipation, is unknown and may be confounded since the seven studies that enrolled the oldest subjects were the same studies that enrolled constipated subjects. The number of treatment effects per strain is limited; B. lactis DN-173 010 (3), B. lactis HN019 (2) and L. rhamnosus GG (2). Drawing definite conclusions is therefore perilous, but the finding that the former two strains have notably greater treatment effects on ITT suggests that these strains could be considered when aiming to relieve slow intestinal transit.
The clinical importance of ITT is highly dependent on the underlying pathology. In healthy adults with no evidence of GI disturbances or delayed transit, there is arguably little benefit in lowering ITT [25] . In contrast to this position, EFSA considers that a reduction in ITT within the normal range to be a possibly beneficial physiological effect in healthy adults [8] . Overall, probiotic supplementation for this sole purpose cannot be strongly recommended given the questionable clinical benefit and the small effect size (SMD: 0.17) identified in this meta-analysis. In adults with constipation or IBS, a reduction in ITT is moderately associated with improvements in stool form and frequency [25, 26] . Therefore, probiotic supplementation appears to be a reasonably effective option to achieve this therapeutic goal provided diarrhea does not develop. Current evidence suggests that probiotics contribute to lowering intestinal pH, decreasing colonization and invasion by pathogenic organisms, and modifying the host immune response with few known side effects [27] . However, there is no strong evidence from RCTs that probiotics improve symptoms such as abdominal pain or bloating in these patients [28] . The clinical importance of decreased ITT in the absence of symptom amelioration is controversial and requires further exploration.
Relevance of findings to clinical trial designs
Interestingly, this meta-analysis identified a positive benefit of probiotic supplementation on ITT although only 4 of 13 treatment effects demonstrated such a benefit. This is likely because the majority of clinical trials were underpowered due to small sample size. In fact, only 1 treatment effect was identified from a study with a minimum detectable effect size ≤ 0.5 (moderate effect) and only 5 had a minimum detectable effect size ≤ 0.8 (large effect). Considering the overall ITT SMD with probiotic supplementation is only 0.4, it is clear that small sample size and, consequently, inadequate statistical power was the main driver of the high failure rate of individual studies. The use of estimated SMD is an integral component of study design development and sample size estimation for RCTs. Sample sizes for RCTs based on estimated SMD are shown in Table 7 . Based on the SMDs calculated in this meta-analysis, enrollment of approximately 90 subjects would be required in a study of probiotics for constipation or irritable bowel syndrome-C with a parallel groups design or 19 subjects if utilizing a crossover design. In comparison, for a trial of healthy volunteers, required sample sizes would be 786 and 156 for parallel groups and cross-over designs, respectively, in order to achieve adequate statistical power. Although cross-over trials always require a smaller sample size for a given SMD since subjects serve as their own controls, the main disadvantages of this design include a longer time on study, higher attrition rates due to the extended trial duration, and difficulties in estimating an appropriate washout duration. As such, cross-over designs are inappropriate for clinical trials with extended treatment durations or long or unknown washout periods.
Strengths and limitations
The strengths of this systematic review and meta-analysis include selection of only RCTs to minimize bias and the comprehensive assessment of the impact of moderator variables on the primary outcome. Nevertheless, our analysis was associated with several limitations. First, treatment duration in the reviewed studies ranged from 10 to 28 d and, therefore, the treatment effect of longer term probiotic supplementation on ITT is unknown. Second, the therapeutic benefit of probiotics is considered to be strain-specific; however, the small number of studies performed with each strain prevented robust strain-specific comparisons. Third, there was a significant over-representation of subjects who were young to middle-aged, female, and with a normal body mass index. Abundant caution must be exercised when extrapolating the treatment effects observed in this review to a broader population. Finally, we noted significant heterogeneity among ITT measurement methods as well as product delivery methods and additional included ingredients (e.g., prebiotics) among studies. There is potential for these differences to confound the results of our analysis.
In conclusion, short-term probiotic supplementation decreases ITT with consistently greater treatment effects identified in constipated or older adults and with certain probiotic strains.
COMMENTS
Background
Functional gastrointestinal (GI) disorders are common in the general population, with slow intestinal transit a common symptom. No known therapy is highly efficacious, safe, and cost effective for treatment of slow-transit bowel disorders. Probiotics are live micro-organisms that confer a health benefit on the host when administered in adequate dosages and have been extensively studied for treatment of functional GI disorders.
Research frontiers
Clinical trials of probiotic supplementation on intestinal transit time (ITT) yield widely variable outcomes. The reasons for these discrepant outcomes have not been explored to date. Authors performed the first systematic review and meta-analysis on the efficacy of probiotic supplementation on ITT in adults with a secondary focus on identifying the factors that influence these outcomes.
Innovations and breakthroughs
Authors demonstrated that, overall, short-term (10-28 d) probiotic supplementation reduces ITT in adults. However, the treatment effect of probiotics is strongly dependent on: (1) the presence or absence of constipation; (2) subject age; and (3) probiotic strain.
Applications
The effect of probiotics on ITT is highly dependent on probiotic strain and patient characteristics. The reason for these differences requires exploration in future clinical trials. Thus far, no evidence supports the use of probiotics to decrease ITT in younger subjects or in those without constipation.
Terminology
Probiotics are live micro-organisms that confer a health benefit on the host when administered in adequate dosages. Intestinal transit time is a general term that refers to the time taken for a food bolus to travel through the gastrointestinal system. The standardized mean difference is a statistical measure of effect size for continuous outcomes, defined as the mean difference between groups divided by the pooled standard deviation.
Peer review
Considering the high prevalence of functional GI disorders nowadays and the numerous studies on the role of probiotics in treating such conditions, it is important to know where we stand. This meta-analysis demonstrates the efficacy of probiotic supplementation in improving intestinal transit time. It is very well written, with methods clearly presented. Conclusions are drawn regarding the clinical importance of these findings and their relevance to clinical trials design, representing valuable information.
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